Homology Medicines (NASDAQ:FIXX) Trading Up 6.5%

Shares of Homology Medicines Inc (NASDAQ:FIXX) were up 6.5% during mid-day trading on Friday . The company traded as high as $17.04 and last traded at $16.78, approximately 262,000 shares changed hands during mid-day trading. An increase of 9% from the average daily volume of 240,717 shares. The stock had previously closed at $15.75.

A number of equities analysts recently issued reports on FIXX shares. ValuEngine downgraded shares of Homology Medicines from a “buy” rating to a “hold” rating in a research note on Friday, April 19th. HC Wainwright set a $36.00 price target on shares of Homology Medicines and gave the stock a “buy” rating in a research note on Tuesday, June 11th. Zacks Investment Research raised shares of Homology Medicines from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th. Finally, Canaccord Genuity set a $37.00 price target on shares of Homology Medicines and gave the stock a “buy” rating in a research note on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $29.10.

The stock’s 50 day simple moving average is $18.36 and its two-hundred day simple moving average is $22.06. The firm has a market cap of $692.53 million, a P/E ratio of -8.39 and a beta of 0.15.

Homology Medicines (NASDAQ:FIXX) last announced its earnings results on Thursday, August 8th. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.06). Homology Medicines had a negative net margin of 3,232.67% and a negative return on equity of 38.74%. The business had revenue of $0.39 million for the quarter, compared to the consensus estimate of $1.00 million. On average, analysts forecast that Homology Medicines Inc will post -2.41 EPS for the current year.

In other Homology Medicines news, insider Albert Seymour sold 9,300 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $19.90, for a total transaction of $185,070.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Arthur Tzianabos sold 12,500 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $18.98, for a total transaction of $237,250.00. The disclosure for this sale can be found here. Insiders have sold 71,600 shares of company stock valued at $1,402,484 in the last ninety days. Insiders own 33.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp grew its stake in Homology Medicines by 114.0% in the fourth quarter. Bank of New York Mellon Corp now owns 58,527 shares of the company’s stock valued at $1,308,000 after acquiring an additional 31,180 shares during the period. Northern Trust Corp boosted its position in shares of Homology Medicines by 49.6% during the fourth quarter. Northern Trust Corp now owns 181,361 shares of the company’s stock worth $4,055,000 after buying an additional 60,163 shares during the period. Geode Capital Management LLC boosted its position in shares of Homology Medicines by 37.8% during the fourth quarter. Geode Capital Management LLC now owns 153,033 shares of the company’s stock worth $3,421,000 after buying an additional 41,972 shares during the period. Bank of America Corp DE boosted its position in shares of Homology Medicines by 7.1% during the fourth quarter. Bank of America Corp DE now owns 30,439 shares of the company’s stock worth $681,000 after buying an additional 2,027 shares during the period. Finally, MetLife Investment Advisors LLC acquired a new position in shares of Homology Medicines during the fourth quarter worth about $188,000. 53.15% of the stock is owned by institutional investors and hedge funds.

Homology Medicines Company Profile (NASDAQ:FIXX)

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Featured Story: Intrinsic Value

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.